Overview

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

Status:
NOT_YET_RECRUITING

Trial end date:
2027-05-22

Target enrollment:

Participant gender:

Summary

ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.

Phase:

PHASE3

Details

Lead Sponsor:

Oramed, Ltd.

Collaborator:

InClin, Inc.

Treatments:

Insulin
ORMD-0801